CIBICI   14215
CENTRO DE INVESTIGACION EN BIOQUIMICA CLINICA E INMUNOLOGIA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
. Potential vaccine of Kunitz type protein formulated with a nano liquid crystal structure against Fasciola hepatica.
Autor/es:
SILVANE L; CELIAS D; MALETTO B; SANCHEZ VALELCILLO MF; CHIODETTI AL; PALMA SD; ALLEMANDI DA; CERVI L
Lugar:
Bs As
Reunión:
Congreso; IV LASID Meeting. LXIII Argentinean Immunology Society Meeting. II French-Argentinean Immunology Meeting; 2015
Institución organizadora:
LASID-SAI-FAIC
Resumen:
Potential vaccine of Kunitz type protein formulated with a nano liquid crystal structure against Fasciola hepaticaSilvane L1, Celias D1, Maletto BA1,Sánchez Vallecillo M1, Chiodetti A1, Palma D2, Allemandi D2 , y Cervi LD11 Dpto. de Bioq. Clín. Fac. C. Qcas. Univ.Nac.Córdoba. CIBICI-CONICET. Córdoba, Argentina.Fasciola hepatica is a worldwide distributed helminth parasites that causes great economic losses in sheep and cattle. Triclanbendazol has been the drug of choice against fascioliasis. However, the continuing efficacy of this drug is at risk as resistance is emerging. Our research is focusing on developing new approaches, such as effective vaccine therapy, to control this disease.Kunitz type molecule (KTM) is a serine protease expressed in both juvenile and adult stage of the life cycle and is important for parasite feeding. We use a recombinant of KTM formulated with CpG-ODN/Coa-ASC16, a promising adjuvant with capacity for induce response Th1 and Th17.BALB/c mice were subcutaneously immunized with a solution of KTM/CpG-ODN/Coa-ASC16 or CpG-ODN/Coa-ASC16. Immunizations were performed at day 0, 7, 14. CpG-ODN was administered at 75 µg/mouse/dose, KTM at 20 µg/mouse/dose. One week after the last vaccination, mice were challenged orally with 6 F.hepatica metacercariae and euthanized 25 days after challenge.The pathological lesions of liver as well as alanine transaminasa (ALT) levels in vaccinated with KTM/CpG-ODN/Coa-ASC16 were significantly lower when compared with control groups (only infected mice) (p >0.05 Student T Test) indicating that vaccinated mice had reduced liver parenchyma damage. The levels of KTM specific IgG1 detected by ELISA, was significantly incresead in immunized group compared with control infected group.This study suggests that KTM/CpG-ODN/Coa-ASC16 has a potential as a vaccine candidate against F. hepatica in mice, and this possibility could be tested in ruminants.